Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases... Show more
The RSI Oscillator for ACLX moved out of oversold territory on January 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In of the 19 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 44 cases where ACLX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
ACLX moved above its 50-day moving average on February 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACLX advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on February 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACLX as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for ACLX moved below the 200-day moving average on January 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACLX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ACLX broke above its upper Bollinger Band on January 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ACLX entered a downward trend on January 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.116) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (107.527) is also within normal values, averaging (331.843).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ACLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SNOAX | 37.43 | 0.22 | +0.59% |
| Easterly Snow Long/Short Opportunity A | |||
| RRSRX | 31.01 | 0.15 | +0.49% |
| Russell Inv Global Real Estate Secs R6 | |||
| QRSAX | 45.32 | 0.16 | +0.35% |
| FPA Queens Road Small Cap Value Advisor | |||
| OIEIX | 25.27 | 0.07 | +0.28% |
| JPMorgan Equity Income A | |||
| WMGCX | 14.86 | -0.21 | -1.39% |
| Nomura Mid Cap Growth C | |||
A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with RNA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then RNA could also see price increases.
| Ticker / NAME | Correlation To ACLX | 1D Price Change % | ||
|---|---|---|---|---|
| ACLX | 100% | +1.70% | ||
| RNA - ACLX | 53% Loosely correlated | +0.23% | ||
| BEAM - ACLX | 52% Loosely correlated | +1.09% | ||
| ROIV - ACLX | 52% Loosely correlated | +1.48% | ||
| VRDN - ACLX | 51% Loosely correlated | +0.61% | ||
| IDYA - ACLX | 50% Loosely correlated | +5.81% | ||
More | ||||